Trials / Completed
CompletedNCT00193687
Bifeprunox in the Treatment of Schizophrenia
An Open-Label, Flexible-Dose, Long-Term Safety and Efficacy Study of Bifeprunox in the Treatment of Schizpohrenia (Extension of S154.3.001)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 986 (actual)
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia. Extension to study S154.3.001.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bifeprunox |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2005-09-19
- Last updated
- 2008-03-24
Source: ClinicalTrials.gov record NCT00193687. Inclusion in this directory is not an endorsement.